Sun Pharma announces USFDA approval for generic Xanax ® Tablets

Mumbai, June 18, 2010: Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax ®, alprazolam tablets.

These generic alprazolam tablets, equivalent to Pfizer’s Xanax ® tablets, include four strengths: 0.25 mg, 0.5 mg, 1 mg and 2 mg.  Annual sale in US for these strengths of branded and generic alprazolam tablets is estimated at $ 145 million.

Alprazolam tablets are indicated for the management of anxiety disorder or the short-term relief of symptoms of anxiety.  It is also indicated for the treatment of panic disorder, with our without agoraphobia.

Xanax ® is a registered trademark of Pfizer.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company.  It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.  In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology.  The Company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.